2024
HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases.
Vilariño N, Lopez De Rodas M, Ranjan K, Costantini A, Villalba M, Lu B, Kravitz C, Nadal E, Goldberg S, Nguyen D, Schalper K. HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases. Journal Of Clinical Oncology 2024, 42: e14014-e14014. DOI: 10.1200/jco.2024.42.16_suppl.e14014.Peer-Reviewed Original ResearchLung cancer brain metastasisPrimary lung tumorsTumor-infiltrating lymphocytesImmune checkpoint inhibitorsCancer brain metastasesAntigen presentation machineryB2M expressionIFN-gBrain metastasesB2MImmune evasionAssociated with shorter overall survivalMultiplexed quantitative immunofluorescenceM expressionExpression of B2MB2M levelsExpression of pSTAT1Shorter overall survivalUnfavorable clinical featuresNo significant associationAssociated with unfavorable clinical featuresCheckpoint inhibitorsImmunotherapy resistanceProperties of tumorsPresentation machinery
2023
Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm D. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Research Communications 2023, 3: 558-563. PMID: 37057033, PMCID: PMC10088911, DOI: 10.1158/2767-9764.crc-22-0299.Peer-Reviewed Original ResearchConceptsDigital spatial profilingB2M expressionOverall survivalM HNSCCImmunotherapy outcomesNeck squamous cell carcinoma (HNSCC) treatmentHigh beta-2 microglobulinSquamous cell carcinoma treatmentCell death protein 1Neck squamous cell carcinomaM expressionPretreatment biopsy samplesImmune checkpoint inhibitorsPD-L1 expressionImmune checkpoint markersDeath protein 1Squamous cell carcinomaB2MBeta-2-microglobulinBeta 2 microglobulin expressionImproved PFSCheckpoint inhibitorsMetastatic headCheckpoint markersImproved survival
2022
Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.
Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Psyrri A, Rimm D. Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2022, 40: 6050-6050. DOI: 10.1200/jco.2022.40.16_suppl.6050.Peer-Reviewed Original ResearchNeck squamous cell carcinomaM HNSCC patientsSquamous cell carcinomaB2M expressionOverall survivalHNSCC patientsValidation cohortCell carcinomaB2MPre-treatment biopsy samplesUnivariate Cox regression modelM expressionFunctional antigen presentationHigh beta2-microglobulinTreatment of recurrentImmune checkpoint expressionCox regression modelImmune cell markersStandard of careIndependent validation cohortSpatial profiling technologyDigital spatial profilingDigital spatial profiling (DSP) technologyImmune stromaM HNSCC
2021
B2M overexpression correlates with malignancy and immune signatures in human gliomas
Zhang H, Cui B, Zhou Y, Wang X, Wu W, Wang Z, Dai Z, Cheng Q, Yang K. B2M overexpression correlates with malignancy and immune signatures in human gliomas. Scientific Reports 2021, 11: 5045. PMID: 33658560, PMCID: PMC7930032, DOI: 10.1038/s41598-021-84465-6.Peer-Reviewed Original ResearchMeSH Keywordsbeta 2-MicroglobulinBiomarkers, TumorBrain NeoplasmsCarcinogenesisCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticGenomicsGliomaHumansImmune Checkpoint ProteinsImmune ToleranceImmunotherapyIsocitrate DehydrogenaseKaplan-Meier EstimateMutationPrognosisPTEN PhosphohydrolaseTumor MicroenvironmentConceptsB2M expressionImmune signaturesM expressionB2MAssociated with immune checkpoint moleculesAssociated with PTEN deletionSuppress anti-tumor immunityAnti-tumor immunityImmune checkpoint moleculesImmunotherapy of gliomaLimited treatment strategiesStromal cell typesCheckpoint moleculesEGFR amplificationClinical characteristicsPTEN deletionPatient prognosisTumor progressionTreatment strategiesGenomic profilingInflammatory activityImmunotherapySomatic mutationsCGGA databasesGlioma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply